Mangrove Partners Selecta Biosciences Inc Transaction History

Mangrove Partners

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.33 - $2.6 $2.66 Million - $5.2 Million	-2,000,000 Reduced 27.55%	5,260,419 $8.63 Million
Q2 2022 Aug 15, 2022	BUY	$0.67 - $1.4 $4.86 Million - $10.2 Million	7,260,419 New	7,260,419 $9.51 Million
Q1 2021 May 17, 2021	SELL	$2.92 - $5.07 $2.06 Million - $3.58 Million	-705,660 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$1.64 - $3.42 $8.33 Million - $17.4 Million	-5,080,920 Reduced 87.81%	705,660 $2.14 Million
Q3 2020 Nov 16, 2020	SELL	$2.18 - $2.84 $1.66 Million - $2.16 Million	-760,200 Reduced 11.61%	5,786,580 $9.49 Million
Q2 2020 Aug 14, 2020	BUY	$1.83 - $4.06 $1.83 Million - $4.05 Million	997,923 Added 17.98%	6,546,780 $18.6 Million
Q1 2020 May 15, 2020	BUY	$1.5 - $4.52 $441,511 - $1.33 Million	294,341 Added 5.6%	5,548,857 $13.4 Million
Q4 2019 Feb 14, 2020	BUY	$1.32 - $2.47 $6.94 Million - $13 Million	5,254,516 New	5,254,516 $12.5 Million

4.67M

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

Get notified when there are updates to the investment portfolio of Mangrove Partners, based on Form 13F filings with the SEC.

Stay updated on Mangrove Partners with notifications on news.